Athira Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Athira PharmaDer Gewinn des Unternehmens wird voraussichtlich um 9% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 54.2% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 17.7% pro Jahr wachsen.

Wichtige Informationen

-9.0%

Wachstumsrate der Gewinne

17.7%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	54.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Oct 17

Athira Pharma GAAP EPS of -$0.65

Aug 15

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Aug 09

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Jun 22

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

May 08

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Jan 11

Athira Pharma: What, Exactly, Did The CEO Do?

Jun 29

Athira Pharma falls after the decision to place CEO on temporary leave

Jun 17

Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy

Jun 07

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

May 24

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Feb 08

Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach

Jan 11

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Dec 18

Athira Pharma nabs research grant of $15M from NIH

Dec 08

Athira Pharma reports Q3 results

Nov 12

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ATHA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	4	-146	-137	-117	3
12/31/2025	N/A	-127	-133	-136	5
12/31/2024	N/A	-110	-104	-127	6
3/31/2024	N/A	-116	-100	-100	N/A
12/31/2023	N/A	-118	-101	-101	N/A
9/30/2023	N/A	-121	-90	-90	N/A
6/30/2023	N/A	-108	-88	-88	N/A
3/31/2023	N/A	-102	-83	-82	N/A
12/31/2022	N/A	-96	-74	-72	N/A
9/30/2022	N/A	-82	-77	-75	N/A
6/30/2022	N/A	-77	-66	-64	N/A
3/31/2022	N/A	-67	-54	-52	N/A
12/31/2021	N/A	-55	-45	-43	N/A
9/30/2021	N/A	-46	-38	-36	N/A
6/30/2021	N/A	-39	-37	-35	N/A
3/31/2021	N/A	-27	-33	-30	N/A
12/31/2020	N/A	-20	-26	-24	N/A
9/30/2020	N/A	-13	-15	-14	N/A
6/30/2020	N/A	-6	-6	-6	N/A
3/31/2020	N/A	-6	-4	-4	N/A
12/31/2019	N/A	-5	-4	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ATHA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ATHA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ATHA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ATHA wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: ATHA wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ATHA in 3 Jahren voraussichtlich hoch sein wird

Athira Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 23% to US$9.25

Price target decreased by 33% to US$7.83

Price target increased to US$11.75

Price target increased to US$11.75

Price target decreased to US$15.40

Price target increased to US$39.67

Recent updates

Athira Pharma, Inc. Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer

Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Athira Pharma, Inc., Annual General Meeting, May 23, 2024

New minor risk - Market cap size

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer

Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer

Price target increased by 23% to US$9.25

Athira Pharma, Inc. Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-B-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

New minor risk - Market cap size

Athira Pharma, Inc. Appoints Andrew Gengos as Chief Financial Officer

Athira Pharma, Inc. Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease

CFO & Chief Business Officer recently bought US$192k worth of stock

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Athira Pharma, Inc. Announces the Appointment of Andrew Gengos as Chief Business Officer

Athira Pharma, Inc. Announces CFO Changes

Independent Director recently bought US$60k worth of stock

Price target decreased by 33% to US$7.83

Athira Pharma Announces Promotion of Kevin Church to Chief Scientific Officer

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Chief Financial Officer recently bought US$142k worth of stock

Athira Pharma, Inc. Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

Independent Chairwoman of the Board recently bought US$99k worth of stock

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Price target increased to US$11.75

High number of new and inexperienced directors

Athira Pharma Advances Phase 2/3 Lift-Ad Clinical Study of Fosgonimeton in Mild-To Moderate Alzheimer's Patients Following Independent, Unblinded Interim Analysis

Price target increased to US$11.75

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Athira Pharma, Inc. Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients

Athira Pharma GAAP EPS of -$0.65

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022

Price target decreased to US$15.40

Athira Pharma, Inc. Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Athira Pharma, Inc. Announces New Board Appointments

Richard A Kayne Issues Letter to Shareholders of Athira Pharma Inc

Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

Richard A Kayne Communicates with Athira Pharma Inc

Richard A Kayne Communicates with Athira Pharma Inc

High number of new and inexperienced directors

Richard A. Kayne Files an Investor Presentation to Shareholders of Athira Pharma

Richard A. Kayne Files an Investor Presentation to Shareholders of Athira Pharma

Richard A. Kayne Provides Information to Shareholders of Athira Pharma Inc

Athira Pharma, Inc., Annual General Meeting, May 19, 2022

Athira Pharma, Inc. Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions

Independent Chairman of the Board recently bought US$105k worth of stock

Richard A. Kayne Sends Provides Information to Shareholders of Athira Pharma Inc

Athira Pharma, Inc. Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

Athira Pharma, Inc. Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease

Price target increased to US$39.67

Athira Pharma, Inc. Appoints Grant Pickering to Its Board of Directors

Athira Pharma Announces Initiation of Patient Dosing in Shape, a Phase 2 Clinical Trial of ATH-1017

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Price target decreased to US$33.75

High number of new and inexperienced directors

Chief Operating Officer exercised options to buy US$485k worth of stock.

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

The Law Offices of Frank R. Cruz Announces the Filing of Securities Class Action on Behalf of Athira Pharma, Inc. Investors

Athira Pharma: What, Exactly, Did The CEO Do?

Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 3000E Growth Index

Block & Leviton LLP Files Lawsuit Against Athira Pharma, Inc. for Securities Fraud

Athira Pharma falls after the decision to place CEO on temporary leave